Apr 9, 2020

Up-to-date role of biologics in the management of respiratory syncytial virus

Expert Opinion on Biological Therapy
Seyhan Boyoglu-Barnum, Ralph A Tripp

Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease in young children and a substantial contributor to respiratory tract disease throughout life. Despite RSV being a high priority for vaccine development, there is currently no safe and effective vaccine available. There are many challenges to developing an RSV vaccine and there are limited antiviral drugs or biologics available for the management of infection. In this article, we review the antiviral treatments, vaccination strategies along with alternative therapies for RSV. This review is a summary of the current antiviral and RSV vaccination approaches noting strategies and alternative therapies that may prevent or decrease the disease severity in RSV susceptible populations. This review discusses anti-RSV strategies given that no safe and efficacious vaccines are available, and therapeutic treatments are limited. Various biologicals that target for RSV are considered for disease intervention, as it is likely that it may be necessary to develop separate vaccines or therapeutics for each at-risk population.

  • References111
  • Citations1

Citations

Mentioned in this Paper

Antiviral Agents
Disease Management
Respiratory syncytial virus
Vaccines
Respiratory Tract Diseases
Vaccination
Biological Factors

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

© 2020 Meta ULC. All rights reserved